The U.S. private label credit card (PLCC) industry is on track for expansion through 2025, with a nearly 10% anticipated rise in purchase volume and card outstandings. Leading this growth are issuers like Synchrony Financial (NYSE:SYF), which targets over $339 billion in purchases and $172 billion in outstandings by 2025. This optimism is fueled by robust cardholder loyalty programs and the introduction of products such as medical credit cards. Synchrony's CareCredit, a pioneer in the medical credit space since its inception, has seen a significant increase in healthcare provider partnerships and an expanding user base.
The sector's resilience, despite the rising popularity of Buy Now, Pay Later (BNPL) services, can be attributed to innovative offerings that tap into consumer loyalty. These include new credit card products that cater to specific needs like healthcare expenses. The industry's dynamic nature is evident as it continues to evolve and adapt to changing consumer preferences.
However, the industry must navigate potential profitability challenges. Heightened interest rates on balances could lead to increased charge-offs, affecting revenue streams. Additionally, the Consumer Financial Protection Bureau (CFPB) has proposed caps on late fees, which could drastically reduce income from these charges. Such regulatory changes pose a significant threat to profits, especially for subprime borrowers who are more likely to incur late fees.
The PLCC market's growth projections come amidst these financial and regulatory headwinds. As issuers continue to develop distinct loyalty programs separate from traditional PLCC offerings, the industry remains poised for significant financial advancements through strategic diversification and a focus on maintaining customer loyalty amidst a competitive payment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.